

<p>(51) International Patent Classification<sup>4</sup> : C12N 15/00, 1/20 // C12N 9/54</p>	<p>A1</p>	<p>(11) International Publication Number: WO 88/ 06623 (43) International Publication Date: 7 September 1988 (07.09.88)</p>
---	-----------	---

*Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

Transformed prokaryotic hosts are provided comprising two or more copies of a DNA sequence stably maintained in their chromosome, said sequence comprising a gene encoding a polypeptide of interest, wherein said copies are separated by endogenous chromosomal DNA sequences. Methods are also provided for producing said transformed host strains. Said transformed host strains are capable of increased production of the polypeptide of interest compared to host strains which already produce said polypeptide. Preferred host strains are *Bacillus novo* species PB92 which produces a high-alkaline proteolytic enzyme and *Bacillus licheniformis* T5 which produce a thermostable alpha-amylase, and mutants and variants of said strains. Preferred polypeptide encoding genes are the protease encoding gene originating from *Bacillus* PB92 and the alpha-amylase encoding gene originating from *Bacillus licheniformis* strain T5.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

STABLE GENE AMPLIFICATION IN CHROMOSOMAL DNA  
OF PROKARYOTIC MICROORGANISMS

INTRODUCTION

5 Technical Field

The field of this invention relates to prokaryotic cells in which stable gene amplification is obtained by scattered non-tandem integration of at least two copies of a  
10 defined DNA sequence into the chromosome of said prokaryotic cell.

Background

15 Bacilli have been widely used for the production of industrially important enzymes such as alpha-amylase, neutral protease and alkaline or serine proteases (cf. Debabov, "The Industrial Use of Bacilli", in: The Molecular Biology of Bacilli, Acad. Press, New York, 1982). Improvement of  
20 production of Bacillus enzymes can be achieved both by classical genetic techniques, such as mutation and subsequent selection, and by modern molecular biological techniques. In the latter case, several ways of obtaining high levels of expression of homologous and heterologous genes in certain  
25 prokaryotic and eukaryotic microorganisms by genetic engineering have been well documented.

One of the approaches to achieve high level expression of a gene is to provide the gene with efficient regulatory sequences. Another approach, often used in  
30 combination with the first approach, is to increase the copy number of the gene in question. Amplification is primarily achieved by inserting the gene into a multicopy extrachromosomal DNA molecule such as a plasmid. However, a significant drawback of using plasmids as vectors for expressing and  
35 amplifying genetic information has been their instability. For large scale use, stability of the amplified gene is a prerequisite for maintaining high level production of the

expression product encoded by the amplified gene, as many cell divisions have to take place before sufficient biomass is formed for obtaining substantial product formation.

Instability is encountered in two forms:

5 segregational instability, where loss of the plasmid occurs during cultivation; and structural instability, where a part of the plasmid is deleted. Segregational instability can occur, for example, when a host cell is harbouring a vector carrying a gene that is overexpressed. Generally there will be  
10 selective pressure towards cells that have lost the capacity to overexpress the gene, since overexpression is an unfavorable property for the transformed host cell. A large amount of metabolic energy is spent on the overexpressed gene product, which negatively influences the cells' competitiveness (growth  
15 rate) with host cells not likewise overexpressing.

A method used to counter segregational instability is to select for cells containing multicopy plasmids which carry genes which confer an advantage on the plasmid containing cell, for example, conferring resistance to an  
20 antibiotic and then to add the relevant antibiotic to the fermentation broth. However, antibiotics are generally not a useful selection means in large scale commercial production processes due to regulations concerning the approval of the fermentation process or the product itself.

25 Another method used to minimize plasmid loss due to segregational instability is to insert a gene which is functionally essential for the host cell into the vector molecule (Ferrari et al., Biotechnology 3 (1985) 1003-1007). However, this method does not ensure structural stability of  
30 the vector.

Techniques used to solve the problem of structural plasmid instability have included avoiding expression of the gene during the phase of exponential growth, for example, by using regulatory sequences such as temperature-sensitive  
35 regulatory sequences, and integration of the exogenous DNA into the host cell chromosome. Other methods used have included avoiding the use of autonomously replicating vector molecules and instead using techniques which favor integration

of the introduced DNA into the host cell chromosome.

Methods of achieving integration of foreign DNA into the host cell chromosome have included homologous recombination and illegitimate recombination. There are two ways of inserting DNA sequences into specific locations on a chromosome by homologous recombination: Campbell-type homologous recombination and double reciprocal recombination, which are shown in Figures 1A and 1B, respectively. A third way of introducing DNA sequences into the chromosome, this method using a two-step replacement mechanism, is shown in Figure 1C. In principle, a Campbell-type recombination is used, but the final result is a chromosomal arrangement that contains no duplicated sequences, and thus no amplifiable unit, in the recombined part of the chromosome. It therefore resembles a double reciprocal recombination.

Apart from using homologous recombination for the integration of foreign DNA into the chromosome it is also possible to integrate DNA by illegitimate recombination. Integrated vector molecules can be selected for under conditions which inhibit autonomous replication of non-integrated vector molecules. Use of illegitimate recombination for integration is depicted in Figure 1D. The absence of tandem duplications in the obtained chromosomal sequence arrangements make the pathways shown in Figures 1B, C and D preferred for stable introduction of DNA sequences into the genome. Chromosomally integrated genes have included both homologous and heterologous genes where the amplification of the chromosomally integrated DNA has been in a tandem array. These chromosomally amplified sequences have been reported to be unstable although stability has been reported in some cases. It is therefore desirable to develop methods whereby DNA integrated into the chromosome is stably maintained.

#### Relevant literature

35

Integration of exogenous DNA by homologous recombination into the chromosome of Bacillus subtilis has been described by Duncan et al., Proc. Natl. Acad. Sci. USA 75

(1978) 3664-3668 and for Anacystis nidulans by Williams and Szalay, Gene 24 (1983) 37-51 and in International Patent Application WO 84/00381. Integration by homologous recombination of a heterologous gene, which cannot be maintained stably when carried on a plasmid vector, into the chromosome of a microorganism is described in EP-A-0127328.

Amplification of chromosomally integrated genes, both homologous and heterologous has been documented. See for example: Saito et al., Proceedings of the Fourth International Symposium on Genetics of Industrial Microorganisms, Kyoto, Japan, 1982, pp. 125130; Young, J. Gen. Microbiol. 130 (1984) 1613-1621; Janni re et al., Gene 40 (1985) 47-55; Sargent and Bennett, J. Bacteriol. 161 (1985) 529-595; Guttererson and Koshland, Proc. Natl. Acad. Sci. USA 80 (1983) 4894-4898; Hashiguchi et al., Agric. Biol. Chem. 49 (1985) 545-550; Wilson and Morgan, J. Bacteriol. 163 (1985) 445-453; French Patent Application No. 84.06701; and EP-A-0134048. Spontaneous amplification in prokaryotic cells has been reported and can be selected for. See for example the review by Anderson and Roth, Ann. Rev. Microbiol. 31 (1977) 473-505.

In all cases referred to above, amplification of chromosomally integrated DNA was in a tandem array. This type of chromosomal amplification sequence has been reported to be unstable, although rather good stability was found in some cases, as discussed by Janni re et al., Gene 40 (1985) 47-55.

Stabilization of naturally occurring amplified prokaryotic genes due to the presence of other essential genes between these amplified sequences has been reported. For example, of the 9 to 10 copies of the ribosomal RNA gene sets occurring in the B. subtilis chromosome, two tandemly located sets were separated by a cluster of tRNA genes (Wawrousek and Hansen, J. Biol. Chem. 258 (1983) 291-298). In other cases, naturally occurring tandemly repeated ribosomal RNA operons were deleted, both in E. coli and in B. subtilis, with little effect on the phenotypic properties of the organism: Ellwood and Momura, J. Bacteriol. 143 (1980) 1077-1080 and Loughney et al., J. Bacteriol. 154 (1983) 529-532, respectively.

Integration of plasmids into the chromosome of B.

subtilis by illegitimate recombination using the vector pEl94 has been described by Hofemeister et al., Mol. Gen. Genet. 189 (1983) 58-68 and Prorozov et al., Gene 34 (1985) 39-46.

Several genes for extracellular enzymes of bacilli have been successfully cloned, such as the alpha-amylase genes of B. amyloliquefaciens (Palva et al., Gene 15 (1981) 43-51), B. licheniformis (Ortlepp, Gene 23 (1983) 267), B. stearothermophilus (Mielenz et al., Proc. Acad. Sci. USA 80 (1983) 5975-5979; EP-A-0057976) and B. subtilis (Yang et al., Nucleic Acids Res. 11 (1983) 237); the levansucrase gene of B. subtilis (Gay et al., J. Bacteriol. 153 (1983) 1424); the neutral protease encoding genes of B. stearothermophilus (Fuji et al., J. Bacteriol. 156 (1983) 831), B. amyloliquefaciens (Honjo et al., J. Biotech. 1 (1984) 165) and of B. subtilis (Yang et al., J. Bacteriol. 160 (1984) 115; the serine or alkaline protease encoding genes of B. subtilis (Wong et al., Proc. Natl. Acad. Sci. USA 81 (1984) 1184), B. licheniformis (Jacobs et al., Nucleic Acids Res. 13 (1985) 8913) and B. amyloliquefaciens (Wells et al., Nucleic Acids Res. 11 (1983) 7911).

Protoplast transformation for several species of gram positive microorganisms has been reported. For B. subtilis a protocol for protoplast transformation was described by Chang and Cohen (Mol. Gen. Genet. 168 (1979) 111-115), which has been widely used. Similar successful protocols have been described for the transformation of B. megaterium protoplasts (Vorobjeva et al., FEMS Microbiol. Letters 7 (1980) 261-263), B. amyloliquefaciens protoplasts (Smith et al., Appl. and Env. Microbiol. 51 (1986) 634), B. thuringiensis protoplasts (Fisher et al., Arch. Microbiol. 139 (1981) 213-217), B. sphaericus protoplasts (McDonald, J. Gen. Microbiol. 130 (1984) 203), and B. larvae protoplasts (Bakhiet et al., Appl. and Env. Microbiol. 49 (1985) 577); in the same publication unsuccessful results were reported for B. popillae. The protocol was successful for B. polymyxa, B. licheniformis, B. macerans and B. laterosporus but not for B. coagulans, B. cereus and B. pumilus, even though good protoplast formation was observed (Mann et al., Current Microbiol. 13 (1986) 131-135).

Other methods of introducing DNA into protoplasts include fusion with DNA containing liposomes (Holubova, Folia Microbiol. 30 (1985) 97), or protoplast fusion using a readily transformable organism as an intermediate host cell (EP-A-5 0134048).

#### SUMMARY OF THE INVENTION

Prokaryotic host cells, and methods for their  
10 preparation, are provided which comprise at least two copies of a DNA sequence encoding a polypeptide of interest stably integrated into the host cell chromosome. Stable maintenance of the exogenous DNA sequence is obtained by integrating two or more copies of the sequence into the host cell chromosome  
15 wherein the copies are separated by endogenous chromosomal DNA sequences.

#### BRIEF DESCRIPTION OF THE DRAWINGS

20 Figures 1A-D are schematic representations of four ways for integration of extrachromosomal DNA sequences into the chromosome of prokaryotic microorganisms.

T is the target sequence, i.e. DNA sequences present on chromosome and plasmid, between which homologous  
25 recombination can take place.

S stands for the DNA sequence to be integrated in the chromosome.

M stands for a marker gene sequence used for the selection of recombinant strain.

30 Figures 2A and 2B are schematic representations of two ways for obtaining stable gene amplification in a prokaryotic chromosome.

Figure 3 shows the results of histidine/MOPS gel electrophoresis performed on supernatant from cultures of B.  
35 subtilis DB104 containing pUB110 and pM58, respectively, compared with several subtilisins:

lane 1: Carlsberg subtilisin

lane 2: Bacillus PB92 protease



lane 3: Bacillus subtilis subtilisin  
lane 4: Bacillus subtilis DB104 (pM58)  
lan 5: Bacillus subtilis DB104 (pUB110)

Figure 4 shows the restriction map of plasmid pM58.  
5 Furthermore, the sequencing strategy is shown in the upper part of the figure. The arrowed solid lines represent the fragments cloned in the phage M13 vectors mp10, mp11 and mp18. The lower part of the figure shows the sequencing strategy using ten oligonucleotides located at regular distances on the  
10 protease gene.

Figure 5 shows the nucleotide sequence of the coding strand correlated with the amino acid sequence of Bacillus PB92 serine protease. Promoters (P<sub>1</sub>, P<sub>2</sub>), ribosome binding site (rbs) and termination regions (term) of the DNA  
15 sequence are also shown. The numbered solid lines represent the location of the ten oligonucleotides used for sequencing.

Figure 6A shows the construction of plasmid pE194-neo.

Figure 6B shows the construction of plasmid pMAX-  
20 4.

Figure 7A: Digests prepared with HindIII of chromosomal DNA of the strains PB92, PBT109 and PBT108 were subjected to electrophoresis on a 0.5% agarose gel, transferred to nitrocellulose as described by Southern and  
25 hybridized with <sup>32</sup>P labeled nick-translated pM58 DNA. The figure shows an autoradiograph.

Figures 7B and 7C illustrate the integration events occurring in case of homologous (B) recombination and illegitimate (C) recombination between pMAX-4 and the Bacillus  
30 PB92 chromosome.

Figure 8 shows the construction of integration vector pElatB.

Figure 9A illustrates the integration of plasmid pElatB into the chromosome of B. licheniformis strain T9  
35 resulting in B. licheniformis strain TB13.

Figure 9B illustrates the chromosomal recombination of the B. licheniformis strains TB13 and T5 upon protoplast fusion of these strains, resulting in B. licheniformis strain T13F.

Figure 10 shows a chromosomal analysis of nine different colonies isolated from a fermentation of strain T13F as described in Example 11. Isolated chromosomal DNA was digested with EcoRI separated on 0.8% agarose gels and blotted onto nitrocellulose. Hybridization of the blot was performed with <sup>32</sup>P-labeled nick-translated pElatB DNA. The figure shows an autodiagram. The upper arrow indicates the position where an EcoRI DNA fragment of about 15kb migrates which contains the entire pElatB sequence that was integrated into the chromosome on a location not adjacent to the original alpha-amylase gene, as depicted for strain TB13 in Figure 9A. The lower arrow indicates the position where an EcoRI DNA fragment of about 33kb migrates which contains the entire alpha-amylase gene originally present in B. licheniformis strain T5 (see also Figure 9B). The following DNA samples were analyzed:

- lane 1: Bacillus licheniformis T5 DNA
- lane 2: Bacillus licheniformis TB13 DNA
- lane 3: Bacillus licheniformis T390 DNA
- lane 4: DNA from a neomycin-sensitive derivative of Bacillus licheniformis T390, isolated after fermentation, as described in Example 12.
- lane 5: Bacillus licheniformis T13F DNA.
- lanes 6-14: DNA from 9 different colonies isolated from a fermentation of strain T13F as described in Example 12.

#### DESCRIPTION OF THE SPECIFIC EMBODIMENTS

In accordance with the present invention, prokaryotic cells, and methods for their preparation, are provided in which two or more copies of a DNA sequence are stably integrated into the chromosome. A host cell comprising a DNA sequence encoding a polypeptide of interest is transformed with a DNA construct comprising said DNA sequence. Transformed cells in which the integrated DNA sequences are separated by endogenous chromosomal sequences from the gene to be amplified are then selected for. The endogenous intervening sequences

are generally vital to the host cell. Loss of amplified sequences by homologous recombination will be lethal to the host cell. Thus, there will be selection pressure for cells carrying the amplified sequences without the necessity for  
5 using antibiotics or like selection means. Integration may be achieved either by homologous recombination or by illegitimate recombination. Techniques which can be used to obtain the desired cells are as shown in Figures 2A and 2B, respectively.

When homologous recombination is used, several  
10 stretches of DNA sequences can be present in the vector molecules which are homologous to the host cell chromosome, especially when one or more copies of the gene to be amplified have already been introduced into the host cell. The vector molecule thus can include a DNA sequence of interest; a target  
15 DNA sequence; and a marker DNA sequence.

Care has to be taken that only the desired recombined chromosomal arrangements are selected for. This can be achieved by using linear DNA molecules for recombination. The circular vector molecule to be integrated is cut with a  
20 restriction enzyme in the region homologous to the target sequence. In this way recombination and integration at this specific site can occur preferentially. In addition to being present in the vector molecule, the DNA sequence of interest can also be present in the host cell chromosome. The DNA  
25 sequence may be a DNA sequence encoding any structural gene which it is desired to amplify. The DNA sequence may be endogenous to the host organism, or may have been inserted into the host chromosome in a previous transformation step.

Target sequences for non-tandem gene amplification  
30 will preferably be chosen from among non-essential genes, for example in the case of Bacilli as host organisms, the genes encoding extracellular enzymes or genes involved in sporulation can be used as target sequences. Integration of DNA sequences in these genes will generally inactivate the  
35 gene. Loss of expression of the gene can then be monitored and used for the selection of the desired recombinant strains.

When illegitimate recombination is used for chromosomal gene amplification as depicted in Figures 1D and

2A, conditions for integration and selection are preferred in which homologous recombination does not predominate over illegitimate recombination. A preferred means of avoiding homologous recombination is to transform first and second host  
5 cells which lack the structural gene of interest with a vector comprising a DNA sequence encoding a polypeptide of interest, and a marker gene. First and second host cells in which the DNA sequence is present at different locations can then be selected and combined under fusing conditions to yield a  
10 transformed cell with at least two copies of the DNA sequence encoding the structural gene of interest at scattered locations in the second host genome. For ease of selection the first host can be killed prior to fusion.

The gene(s) of interest may be any prokaryotic or  
15 eukaryotic gene. These genes may include bacterial genes, unicellular microorganism genes, mammalian genes, or the like. The structural genes may be prepared in a variety of ways, including synthesis, isolation from genomic DNA, preparation from cDNA, or combinations thereof. The various techniques of  
20 manipulation of the genes are well-known, and include restriction, digestion, resection, ligation, in vitro mutagenesis, primer repair, employing linkers and adapters, and the like. Thus, DNA sequences obtained from a host may be manipulated in a variety of ways, depending upon the require-  
25 ments of the DNA construction. See Maniatis et al., Molecular Cloning, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982.

The structural genes may express a variety of polypeptides or proteins, such as enzymes, hormones, lymphokines,  
30 surface proteins, blood proteins, structural proteins, immunoglobulins, or the like, from mammals, unicellular microorganisms, e.g., bacteria, fungi, such as yeast, or filamentous fungi, algae, protozoa, etc., plants or other DNA source. Of particular interest are enzymes, more particularly proteases  
35 and amylases. Illustrative of such enzymes are serine and non-serine proteases, including high alkaline serine proteases, alpha- and beta-amylase, and the like. A preferred source for a serine protease is Bacillus novo species PB92, and for an

alpha-amylase is B. licheniformis strain T5, as well as mutants and variants of these strains.

The gene that forms part of the suitable vector can be obtained by methods generally known in the art. Generally, the method comprises preparing a genomic library from the organism expressing a high alkaline protease. The genomic library is conveniently prepared for example by ligating DNA fragments of the donor strain into a suitable vector.

By the term "suitable vector" is meant a DNA construct comprising a structural gene encoding a protein of polypeptide of interest. The structural gene is joined in proper orientation to control regions such as a promoter sequence, a sequence forming the ribosome binding site and sequences controlling termination of transcription and translation of the structural gene, which control regions are functional in the host cell. Where the host cell has transformation and integration frequencies which are too low to permit direct selection for integration without intermediate isolation of plasmid containing cells, such as industrial Bacillus strains, the vector can additionally comprise an origin of replication that is capable of replicating autonomously in the host cell.

Where the gene is obtained from a donor cell which has transcriptional and translational initiation and termination regulatory signals which are recognized by the host prokaryotic cell strain, it will usually be convenient to maintain the original regulatory sequences of the structural gene. In addition, the transcriptional initiation region may provide for constitutive or inducible expression, so that in appropriate situations, the host may be grown to high density before high levels of expression of the structural genes of interest are obtained.

Where the structural gene is from a source whose regulatory signals are not recognized by the host cell, it will be necessary to obtain regulatory regions recognized by the host cell and to insert the structural gene between the initiation and termination regulatory signals. In some instances the exogenous structural gene with its own stop

codon(s) may be inserted in reading frame behind the N-terminus codons of an endogenous structural gene which retains its natural regulatory signals.

It is desirable that the expression product be  
5 secreted. Where the expression product is naturally secreted and the leader signals and processing signal(s) are recognized by the host cell, this will entail no difficulty. However, where the product is not secreted because the host cell does not recognize the secretory leader signals and/or processing  
10 signal(s), or the signals are not functional to a satisfactory degree in the host cell, then it may be necessary to isolate or synthesize DNA sequences coding for the secretory leader signals and processing signal(s) of a host cell polypeptide and join them in proper reading frame to the 5'-end of the  
15 structural gene.

The vector may additionally include a marker gene conferring resistance to an antibiotic to which the host strain is sensitive. The marker gene, when used in chromosomal integration of the vector, has to fulfill the demand that  
20 survival selection is possible even if only one or a few copies of the marker gene are present in the host strain. By marker is intended a structural gene capable of expression in a host, which provides for survival selection. By "survivial selection" is intended imparting prototrophy to an auxotrophic  
25 host, biocide or viral resistance. For prototrophy, various genes may be employed, such as leu, his, trp, or the like. For biocide resistance this may include resistance to antibiotics, e.g., neo, cam, tet, tun, kan, or the like. Other markers include resistance to heavy metals, immunity, and the like.  
30 The various DNA sequences may be derived from diverse sources and joined together to provide for a vector which includes one or more convenient, preferably unique, restriction sites to allow for insertion or substitution of the structural genes at such sites or in place of lost fragments to provide the  
35 plasmid construct.

Selection for chromosomal integration may be aided by using a plasmid with an origin replication having a mutation which makes its functioning temperature-sensitive in

the host cell. See, for example, Ehrlich, Proc. Natl. Acad. Sci. USA 75 (1978) 1433.

Once the plasmid construct has been prepared, it may now be cloned in an appropriate cloning host. Any host may be used which is convenient, is readily transformable, and allows for replication of the plasmid construct and transfer to the host cell. A large number of strains are available which have a high efficiency of transformation and are usually auxotrophic and/or antibiotic sensitive. Where the host cell is an industrial Bacillus strain, the use of the same organism as the host cell for cloning of the plasmid construct has many advantages in that it permits the use of a single replication system as well as the same marker for survival selection in both the cloning host and the host strain. See, for example, European application EP-A-134048, which disclosure is incorporated herein by reference.

The plasmid construct may be introduced into the cloning host in accordance with conventional techniques, such as transformation, employing calcium precipitated DNA, conjugation, or other convenient technique. The cloning host may then be grown in an appropriate nutrient medium, under selective conditions to select for a host containing the plasmid construct. For auxotrophic hosts, the nutrient medium is deficient in the required nutrient, while for biocide resistance, e.g., antibiotic resistance, a cytotoxic amount of the biocide(s) is employed in the nutrient medium.

Various host cells may be employed. These include E. coli, Bacillus strains, especially Bacillus subtilis, Pseudomonas, and Streptomyces. In choosing a host cell, various factors are taken into account, including factors which can affect expression of the gene to be amplified and production of the desired product. Thus it is desirable to use a host cell in which there is recognition of regulatory signals; ease of secretion; reduced degradation of the desired product, etc. A preferred host cell already produces the polypeptide of interest, and may be either a wild type organism or a mutant organism. The host cell can also be a mutant of an organism which produces the polypeptide of

interest which itself, however, is non-producer. Where the polypeptide of interest is a protease or an amylase, preferred strains include Bacillus novo species PB92 and Bacillus licheniformis strain T5, respectively, as well as mutants and 5 variants of these strains.

In addition, industrial strains may be employed which have the desired traits of an industrial strain. Examples of strains which may be employed include strains used for the industrial production of enzymes such as: B. licheni-  
10 formis, B. amyloliquefaciens and alkalophilic Bacilli. The industrial strains are chosen from organisms which may be isolated in the soil or available from depositories or other sources or obtained by modification of such strains. The industrial strains are highly robust and stable. Furthermore,  
15 said strains are resistant to phage infection and to genetic exchange, that is introduction of DNA by conventional transformation procedures. The conventional industrial strains are also prototrophic, in order to avoid adding expensive amino acids to the nutrient medium. Other characteristics of  
20 industrial strains are their high productivity until the end of the fermentation, which can be as long as a week, stable cell concentration upon exhaustion of the broth, and high productivity, usually at least 5 g/l (0.5% w/v) of a specific secreted protein.

25 Transformants can be obtained having genes either in tandem arrangement or scattered in the chromosome. In general, it is possible to select transformants containing scattered genes from mixtures of the two types of transformants mentioned, by isolating chromosomal DNA of each  
30 individual transformant, subsequently analyzing said DNA with respect to the relative locations of said genes by, for example, the method of Southern, J. Mol. Biol. 98 (1975) 503-517 or other means known to those skilled in the art, thereby identifying scattered integration of said genes.

35 Means for obtaining scattered gene transformants avoiding tandem integration include, using double reciprocal recombination as illustrated in the Figure 1B and 2B, the use of linearized DNA constructs comprising the DNA sequence to be



amplified, a marker gene and target sequences for recombination.

Furthermore, specific means for obtaining scattered gene transformants include the use of illegitimate recombination as illustrated in Figure 2A, in which isolation of tandem transformants can be avoided by selection, using differential expression of a marker gene, for example a gene encoding antibiotic resistance, where sensitivity to the antibiotic is different in strains with tandem integration of the gene as opposed to non-tandem integration. Generally, the length of the intervening endogenous DNA sequences will be less than 10 kbp.

Additionally, means for obtaining scattered gene transformants avoiding tandem duplication include the use of killed protoplasts of a homologous donor strain carrying a DNA construct comprising the structural gene and a marker gene, the structural gene being integrated in the chromosomal at a different location with respect to the acceptor strain.

Transformation of the host cells preferably involves the use of protoplasts prepared from the host strain. Protoplasts generally are prepared from the cells in accordance with conventional ways, e.g. lysozyme or zymolyase treatment, and the protoplasts carefully suspended in an appropriate medium having proper osmolalities for maintaining the integrity of the protoplast. For industrial Bacillus strains, methods for preparing protoplasts are described in EP-A-0134048, which disclosure is incorporated herein by reference. Where the host strain is an alkalophilic Bacillus strain, protoplasts may conveniently be prepared at alkaline pH, preferably about pH 8.0. This procedure is disclosed in European Application No. EP-A-87200358.7, which disclosure is incorporated herein by reference.

The host cell can be transformed by combining the plasmid construct or a cloning host protoplast with the host cell protoplast in the presence of an appropriate fusogen. Any fusogen may be employed which provides the desired degree of efficiency, for the most part polyethylene glycol is found to provide high efficiency of fusion with great convenience.

After a short time, the fusogen mixture is replaced with an appropriate nutrient medium and cells regenerated in a selective medium, conveniently by plating on an agar plate.

Transformants obtained by combining a host cell  
5 with a suitable DNA construct can contain said DNA construct or part thereof either directly as an integral part of their chromosome or as free vector molecules when the DNA constructs contain an origin of replication functional in said host cell.

A means of selecting for transformants wherein the  
10 DNA construct is integrated into the chromosome is to use a plasmid containing a temperature-sensitive origin of replication. Transformants are grown in a selective medium at the permissive temperature, then shifted to a non-permissive temperature. Colonies expressing the marker gene at the non-  
15 permissive temperature are then isolated and cultured in selective medium at the permissive temperature. Plasmid absence can be verified, for example, by isolating total DNA from the colonies and electrophoresising on an agarose gel or by demonstrating lack of ability of the transformants to  
20 transform competent cells. Determination of the way in which integration into the chromosome has taken place can be analysis of the chromosomal DNA by, for example, the method of Southern, J. Mol. Biol. 98 (1975) 503-517 or other means known to those skilled in the art.

25 When there is a differential sensitivity to the selective agent between transformants containing additional copies of the marker gene in a tandem array as compared to those in which the marker gene is incorporated at scattered locations in the host genome, transformants can conveniently  
30 be grown in medium containing the appropriate concentration of selective agent, to select for transformants with non-tandem integration.

Another means of obtaining transformants with scattered integration of copies of the DNA sequence of  
35 interest is to use a protoplast prepared from a homologous donor cell, containing at least one copy of the DNA sequence of interest at a location on its chromosome different from that of the recipient host cell. The homologous donor cell can

be prepared, for example, by transforming a cell which does not contain the structural gene of interest with a vector comprising the structural gene. Integration of the DNA sequence into the donor cell chromosome can be facilitated by using a plasmid containing a temperature-sensitive origin of replication and growing transformants under selective conditions first at the permissive temperature and then at the non-permissive temperature as described above, then isolating colonies expressing the marker gene.

10           Following verification of the absence of plasmid DNA, the chromosomal DNA can be isolated and analyzed according to the method of Southern, supra, by hybridizing with a probe labeled with, for example,  $^{32}\text{P}$  or biotinylated nucleotides. The probe may be cDNA encoding the polypeptide of interest or fragments thereof as well as DNA constructs or fragments thereof comprising the DNA sequence of interest, for example a vector. Transformants containing the gene of interest at an alternate location as compared to that of the gene donor strain can then be used as an homologous donor cell. The recipient strain host is preferably the same as the strain used as the source of the DNA sequence of interest, or a strain in which the DNA sequence of interest is located at a different region of the chromosome than in the transformed donor cell.

25           To aid in selection, the donor cell preferably is killed with a cytotoxic agent prior to or during protoplast formation. Various agent may be employed to kill the donor cell, including antibiotics, but iodoacetamide is found to be convenient, efficient, and does not interfere with the subsequent fusion. When dead cloning host protoplasts are used, the ratio of dead protoplast to the acceptor strain host will be preferably at least about 1:1 and an excess of the dead protoplast may be employed.

35           Following fusion of the dead donor cell protoplast and the recipient host cell protoplast, transformants can be selected by means of the marker gene. DNA can then be isolated and analyzed as described above to identify transformants in which more than one copy of the gene of interest has been

incorporated into the genome and are separated by endogenous chromosomal sequences.

Scattered two-gene transformants are then screened in appropriate ways for detection of increased expression of the polypeptide of interest. Various techniques may be employed, particularly where enzymes are involved which have well established methods of detection. Alternatively, where enzymes are not involved or there is no available detection system, bioassays, antibodies, or DNA or RNA hybridization can be employed for screening the clones to determine the presence of the plasmid construct and expression of the structural gene of interest.

The host cell containing the chromosomally integrated plasmid constructs or fragments thereof is then grown in a nutrient medium under conventional fermenting conditions. The fermenting may be continued until the broth is exhausted. Where the product has been secreted, the product may be isolated from the broth by conventional techniques, e.g., extraction, chromatography, electrophoresis, or the like. Where the product is retained in the cytoplasm, the cells may be harvested by centrifugation, filtration, etc., lysed by mechanical shearing detergent, lysozyme, or other techniques and the product isolated as described previously. By employing the subject method, stable integration of at least two copies of a DNA sequence can be achieved as a means of gene amplification.

The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

EXAMPLE 1

5      Preparation of a Genomic DNA Library from  
         Alkalophilic Bacillus novo sp. PB92 and  
         Isolation of the Serine Protease Gene

Chromosomal DNA isolated from Bacillus novo sp.  
10 PB92 (deposited under No. OR-60 with Laboratorium voor  
Microbiologie, Technical University of Delft, the Netherlands,  
see U.S. Patent No. Re. 30,602) according to the procedure  
described by Saito-Miura, Biochim. Biophys. Acta 72 (1963)  
619-632, was partially digested with the restriction enzyme  
15 Sau3A and ligated into the BamHI site of plasmid pUB110  
(Gryczan et al., J. Bacteriol. 134 (1978) 318-329). pUB110  
plasmid DNA was prepared as described by Birnboim and Doly  
(Nucl. Acids Res. 7 (1979) 1513-1523).

The ligation mixture was transformed into B.  
20 subtilis 1A40 (Bacillus Genetic Stock Centre) according to the  
method of Spizizen et al., J. Bacteriol. 81 (1961) 741-746,  
using 0.6-1 µg DNA per ml of competent cells. Cells from the  
transformation mixture were plated on minimal plates  
containing: 2.8% K<sub>2</sub>HPO<sub>4</sub>, 1.2% KH<sub>2</sub>PO<sub>4</sub>, 0.4% (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.2%  
25 tri-Na-citrate.2H<sub>2</sub>O, 0.04% MgSO<sub>4</sub>.7H<sub>2</sub>O, 0.00005% MnSO<sub>4</sub>.4H<sub>2</sub>O,  
0.4% L-glutamic acid, 0.5% glucose, 0.02% casamino acids, 50  
µg/ml tryptophan, 20 µg/ml methionine, 20 µg/ml lysine, 20  
µg/ml neomycin, 0.4% casein and 1.5% agar. After overnight  
incubation of the plates at 37°C one out of 50,000 neomycin  
30 resistant colonies showed increased protease production, as  
determined by increased precipitation of a halo of casein  
cleavage products around the colony in the agar plate. Plasmid  
DNA was isolated from this colony according to the method  
described by Birnboim and Doly, Nucleic Acids Res. 7 (1979)  
35 1513-1523, and named pM58.

## EXAMPLE 2

### Expression of the PB92 Serine Protease Gene

5. Bacillus subtilis 1A40 containing pM58 was grown in minimal medium (Spizizen et al., Proc. Natl. Acad. Sci. USA 44 (1958) 1072-1078) to which had been added 0.02% casamino acids 50 µg/ml tryptophan, 20 µg/ml methionine, 20 µg/ml lysine and 20 µg/ml neomycin. After 24 hours, the culture was centrifuged 10 and the supernatant assayed for protease activity using dimethyl casein as substrate (Lin et al., J. Biol. Chem. 244 (1969) 789-793. A culture of B. subtilis 1A40 containing the plasmid pUB110 used as a control showed less than 1/60 of the protease activity shown by the pM58 transformed culture.
- 15 Protease activity was completely inhibited by treatment with 1 mM phenylsulfonyl fluoride (PMSF), but not by treatment with 20 mM EDTA.

Aliquots of the above described supernatants were analyzed on protein gel according to the method of Laemmli, 20 Nature 227 (1970) 680. Samples for analysis on these gels were prepared by treatment of the supernatants with 5% trichloroacetic acid (TCA). Following centrifugation of the sample the pellet of precipitated protein was washed twice with acetone then dissolved in 40 µl sample buffer (0.5 M Tris/HCl pH 7.5, 25 10% v/v 2-mercaptoethanol, 50% v/v glycerol and 0.05% Bromophenol Blue) by boiling for 10 minutes. After electrophoresis, the gels were stained using Coomassie Brilliant Blue. Culture supernatant samples were then analyzed by electrophoresis.

Three different B. subtilis 1A40 strains were used: a strain 30 containing pUB110; or pM58; or no plasmid; and Bacillus PB92 protease as a control. After electrophoresis, the gels were stained using Coomassie Brilliant Blue and destained. The sample from B. subtilis strain 1A40 containing pM58 contained a 31 kD protein, which comigrates with Bacillus PB92 protease.

35 This protein was not detected on the control lane of strain B. subtilis 1A40 containing pUB110.

All serine proteases have similar molecular weights. The cloned serine protease of Bacillus PB92 therefore

was differentiated from known serin proteases (B. subtilis subtilisin, Carlsberg subtilisin), by transformation of pM58 and pUB110 to the protease negative B. subtilis strain DB104 (R. Doi, J. Bacteriol. 160 (1984) 442-444) and analysis of the 5 extracellular proteases produced. The obtained transformants were grown in minimal medium (Spizizen et al., supra) containing 0.02% casamino acids, 50 µg/ml histidine and 20 µg/ml neomycin. After 24 hours, samples were taken, centrifuged and without pretreatment analysed on histidine/MOPS gels 10 containing 75 mM KOH, 40 mM histidine, 100 mM MOPS (3-(N-morpholino)-propanesulfonic acid), pH 7.5 and 5% polyacrylamide. Electrophoresis buffer contained 40mM histidine, 100 mM MOPS, pH 6.6. Samples were run in the direction of the cathode. Protease bands were detected with Agfa Pan 100 15 Professional films (Zuidweg et al., Biotechnol. and Bioengin. 14 (1972) 685-714). These results are shown in Figure 3. As shown in Figure 4, pM58 harbours the gene encoding Bacillus PB92 protease.

20

### EXAMPLE 3

#### Sequencing of the Bacillus PB92 Serine Protease Gene

25 The entire sequence of a BalI-HpaI fragment of pM58 was determined by the method of Sanger, Proc. Natl. Acad. Sci. USA 74 (1977) 6463. Restriction fragments of pM58 (see Figure 4) were cloned in phage M13 vectors mp10, mp11 and mp18 (Messing et al., Nucleic Acids Res. 9 (1981) 309-321. Insert- 30 ions of pM58 fragments were screened by plaque hybridization. After sequencing, ten oligonucleotides located at regular distances on the gene were made and sequencing was repeated, confirming the sequence shown in Figure 5.

35

#### EXAMPLE 4

##### Construction of Serine Protease Containing Plasmid pMAX-4

5

To construct plasmid pUCN710 (Figure 6A) pUB110 was digested with TaqI and PvuII. The fragment containing the gene conferring neomycin resistance was purified on low melting agarose and made blunt with Klenow polymerase and NTP's  
10 (Maniatis, Molecular Cloning: A Laboratory Manual. Cold Spring Harbor 1982). Plasmid pUC7 (Vieira et al., Gene 19 (1982) 259-268) was linearized with SalI and made blunt as described above. Both fragments were ligated with T4 ligase (Maniatis) and transformed to E. coli JM103. Selection took place on 2xTY  
15 plates (1.6% w/v Bacto-trypton, 1% w/v yeast extract, 0.5% NaCl) containing 50 µg/ml ampicillin and 10 µg/ml neomycin. The resulting plasmid, named pUCN710, was digested with BamHI. The plasmid pE194 (Jordanescu, Plasmid 1 (1978) 468-479) was digested with BclI. The fragments from both digestions were  
20 ligated with T4 ligase and transformed to B. subtilis 1A40. Selection took place on minimal plates containing 20 µg/ml neomycin (see Example 1). The plasmid obtained, pE194-neo (Figure 6A) contains the neomycin gene and a temperature sensitive origin of replication.

25

Subcloning of the protease gene in integration vector pE194-neo was performed as follows: pV58 (see Example 1) was digested with HpaI and BalI and BglII. Plasmid pE194-neo was digested with HpaI. These fragments were ligated with T4 ligase and transformed to B. subtilis 1A40. Transformants  
30 were selected based upon neomycin resistance and an increase in protease production, as judged by casein cleavage products precipitation (halo formation, see Example 1). Plasmid pMAX-4 was obtained, the structure of which was confirmed by restriction enzyme analysis (see Figure 6B).

35



EXAMPLE 5

Protoplast Transformation of  
Bacillus Strain PB92 by pMAX-4

5

Bacillus strain PB92 was grown overnight in 100 ml NBSG-X medium (Thorne et al., J. Bacteriol. 91 (1966) 1012-1020). The culture was centrifuged for 10 minutes at 4,500 rpm in a Sorvall model GSA rotor. Protoplasts were prepared by incubating the bacilli for one hour at 37°C in 10 ml Alkalic Holding Medium (AHM) containing 0.5 M sucrose, 0.02 M MgCl<sub>2</sub> and 0.02 M Tris/maleate, pH 8.0, in sterile water to which 0.4 mg/ml lysozyme was added. The protoplasts were pelleted (10 minutes at 4,500 rpm), resuspended in 5 ml AHM<sup>+</sup> pH 8.0 buffer (AHM buffer to which 3.5% w/v Bacto Penassay Broth and 0.04% w/v Albumine Merieux had been added) mixed, then repelleted as above. After being resuspended in 5.0 ml of alkaline holding medium, 0.5 ml of this suspension of protoplasts were mixed with 5 µg of demineralized water containing 1 µg of plasmid DNA and incubated for 2 minutes in the presence of 30% w/v polyethylene glycol 8,000, pH 8.0. After 1:3 dilution with AHM<sup>+</sup> pH 8.0 medium and centrifugation, the pellet was resuspended in a small volume (1 ml) of AHM<sup>+</sup> and incubated for 2-3 hours. One hundred microliter aliquots were plated on freshly prepared regeneration plates containing 0.5 M Na succinate/HCl pH 8.0, 1.5% w/v agar, 0.5% w/v casamino acids, 0.5% w/v yeast extract, 0.031 M phosphate buffer pH 8.0, 0.5% w/v glucose, 0.02 M MgCl<sub>2</sub> and 0.02% w/v Albumine Merieux. These plates also contained 1000 µg/ml neomycin for selection. After incubation at 37°C for at least 72 hrs, the colonies were replica-plated onto heart infusion agar plates containing 20 µg/ml neomycin.

EXAMPLE 6

35

Integration of pMAX-4 in the  
Bacillus Strain PB92 Chromosome

A transformant of Bacillus PB92, containing plasmid pMAX-4, was incubated in Tryptone Soya Broth (TSB) containing either 1 µg/ml or 20 µg/ml neomycin for 24 hrs at 37°C. Two ml portions of the cell suspensions were then diluted in 100 ml of TSB containing 1 µg/ml or 20 µg/ml neomycin, respectively, and incubated for 24 hrs at 50°C. After 24 hrs 5 ml samples of both cultures were diluted again, as described above, and incubated for 24 hrs at 50°C, again in the presence of 1 µg/ml or 20 µg/ml neomycin, respectively. The last procedure was repeated once more. The cell suspensions were then diluted 100-fold and plated on Heart Infusion (HI) agar plates containing 1 µg/ml neomycin for the samples from the flasks containing 1 µg/ml neomycin, and 20 µg/ml neomycin for the samples from the flasks containing 20 µg/ml neomycin. The plates were incubated for 16 hrs at 50°C. Neomycin-resistant colonies were isolated and cultured in 10 ml TSB medium containing 1 µg/ml neomycin for 16 h at 37°C. From these cultures total DNA was isolated (Holmes et al., Anal. Biochem. 114 (1981) 193-197. Plasmid absence was verified by DNA electrophoresis on agarose gel. Absence of plasmid DNA from samples in which plasmid DNA was not detectable was confirmed by transformation of total DNA to B. subtilis 1A40. Samples lacking the ability to transform B. subtilis 1A40 were considered plasmid-free.

To check whether and in what way integration of pMAX-4 in the chromosome took place, chromosomal DNA was isolated, digested with HindIII, run on 0.5% DNA agarose gels and blotted to nitrocellulose (Southern, J. Mol. Biol. 98 (1975) 503-517), and hybridized with <sup>32</sup>P labeled nick-translated pM58 (Maniatis, 1982). The result of this analysis is shown in Figure 7A.

Selection at 1 µg/ml neomycin resulted in protease genes tandemly located in the chromosome and separated by plasmid sequences (strain PBT109) as a result of homologous recombination (Campbell-type mechanism). In an accumulation of 30 independently isolated integrants, selection was performed at 1 µg/ml neomycin. One integrant was isolated which contained the plasmid pMAX-4 on a random location in the

chromosome as a result of an illegitimate recombination (strain PBT122). Selection at 20 µg/ml neomycin resulted in a copy of plasmid pMAX-4 on a random location in the chromosome as a result of an illegitimate type of recombination. The latter strain was named PBT108. The genetic organization of the strains PBT109 and 108 are depicted in Figures 7B and 7C, respectively. Chromosomal analysis showed that integration in PBT122 and PBT108 occurred on different locations in the chromosome.

10

#### EXAMPLE 7

##### Stability of the Duplicated Protease Genes in Strains PBT108 and PBT 109

15

One hundred ml of production medium (containing: 1% starch, 4% lactose, 0.87%  $K_2HPO_4$ , 0.5% yeast extract, 0.5%  $(NH_4)_2HPO_4$ , 0.2% Tri Na citrate.  $2H_2O$ , 0.05%  $MgSO_4 \cdot 7H_2O$ , 0.07%  $CaCl_2$ , 0.068%  $FeSO_4 \cdot 7H_2O$  and antifoam 1 ml/l) without neomycin was inoculated with 0.2 ml of an overnight TSB culture (37°C) of strain PBT108 or PBT109 in 500ml shake flasks. After incubation for 44 hrs at 37°C under constant aeration the culture was tested for neomycin-resistant colonies and for protease activity.

25 Both strains PBT108 and PBT109 were also tested in Eschweiler fermenters containing the same production medium to check the effect of upscaling to 10 l. The results of the fermentation experiments are summarized in the following Table 1.

30

Table 1

Strain	Relative Production of Protease*	Percent of Neomycin- Resistant Cells After Fermentation
Control (PB92)	100%	-
PBT108	120%	100%
PBT109	115-120%	75-97%

35

\* Protease activity was assayed using dimethylcasein as substrate as described by Lin et al., J. Biol. Chem. 244 (1969) 789-793.

5                    Analysis of colonies derived from the Eschweiller fermentation of PBT109 after 2 days of culturing, showed that 3-25% of these colonies produced at the level of a strain containing only a single protease gene. These same colonies were found neomycin-sensitive due to excission of the pMAX-4  
10 sequence by homologous recombination. However, analysis of the colonies derived from the strain PBT108 fermentation experiment showed that these cells were all neomycin-resistant. One hundred of these neomycin-resistant colonies were taken at random and individually tested for protease  
15 production potential, to determine whether they contained one or two productive protease genes. All 100 individually tested colonies produced at the level of a strain containing two genes, showing that the two randomly integrated protease genes in PBT108 are stably maintained under the fermentation  
20 conditions used.

#### EXAMPLE 8

##### Construction of Integration Vector pElatB

25

Plasmid pGB34, described in EPA 0134048, was digested with the restriction enzymes BclI, BglI and BglII. The restriction fragments obtained were blunt-ended with Klenow polymerase, then were ligated into the HpaI site of  
30 pE194-neo (see Example 6). Plasmid pE194-neo DNA was isolated as described by Birnboim and Doly (Nucl. Acids. Res. 7 (1979) 1513-1523).

The ligation mixture was transformed into B. subtilis 1-A40, according to the method of Spizizen et al (J. Bacteriol. 81 (1961) 741-746) using 0.5-1 µg DNA per ml of  
35 competent cells. Cells from the transformation mixture were plated on minimal plates containing 2.8% K<sub>2</sub>HPO<sub>4</sub>, 1.2% KH<sub>2</sub>PO<sub>4</sub>, 0.4% (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.2% Tri Na citrate.2H<sub>2</sub>O, 0.04% MgSO<sub>4</sub>.7H<sub>2</sub>O,

0.00005%  $\text{MnSO}_4 \cdot 4\text{H}_2\text{O}$ , 0.4% glutamic acid, 0.5% glucose, 0.02% casamino acids, 50  $\mu\text{g/ml}$  tryptophan, 20  $\mu\text{g/ml}$  methionine, 20  $\mu\text{g/ml}$  lysine, 20  $\mu\text{g/ml}$  neomycin, 0.4% casein, 0.5% starch and 1.5% agar.

5 DNA of alpha-amylase producing colonies was isolated as described by Birnboim and Doly and checked with restriction enzymes. From one of these transformants plasmid pElatB, see Figure 8, was isolated.

10

## EXAMPLE 9

Transformation of the Alpha-Amylase Negative Strain  
Bacillus licheniformis T9 with pElatB

15 Transformation of Bacillus licheniformis strain T9 was carried out as described in EP-A-0253455 with the exception that the entire procedure was performed at 30°C instead of 37°C. Selection for transformants was carried out on minimal plates containing 20  $\mu\text{g/ml}$  neomycin. All trans-  
20 formants produced amylase. Restriction enzyme analysis performed on DNA prepared as described by Birnboim and Doly showed that the transformants all contained pElatB.

## EXAMPLE 10

25

Integration of pElatB into the  
B. licheniformis T9 chromosome

Bacillus licheniformis strain T9 containing plasmid  
30 pElatB, was inoculated in Tryptone Soya Broth (TSB) containing 20  $\mu\text{g/ml}$  neomycin and incubated for 16 hours at 30°C. A 5 ml portion of the cell suspension was diluted in 100 ml of the same medium and incubated at 50°C for 24 hours.

This procedure was repeated once. The cell  
35 suspension was then diluted 100-fold and plated on Heart Infusion Agar plates containing 10  $\mu\text{g/ml}$  neomycin. After 40 hours of incubation at 50°C, neomycin-resistant colonies were isolated and cultured in 10 ml TSB medium, containing 10  $\mu\text{g/ml}$ .

neomycin, for 16 hours at 30°C. Total DNA from these cultures was isolated (Holmes et al., Anal. Biochem. 114 (1981) 193-197). The absence of plasmids in these cells was verified by DNA electrophoresis on agarose gels. Samples in which low molecular weight DNA was virtually absent, were rechecked on the presence of plasmid DNA by DNA transformation to B. subtilis 1-A40 (Spizizen et al., 1961). Samples lacking the ability to transform B. subtilis 1-A40 to neomycin resistance were considered plasmid minus.

10 To check whether integration of pElatB took place and how it took place, chromosomal DNA was isolated from the transformants (Saito-Minwa, Biochem. Biophys. Acta 72 (1963) 619-632), digested with EcoRI fractionated on 0.5% agarose gels, blotted onto nitro-cellulose (Southern, J. Mol. Biol. 98 15 (1975) 503-517) and hybridized with <sup>32</sup>P labeled nick-translated pGB33 (see EP-A-0134048). The results from this analysis are shown in Figure 9A. The data show that illegitimate recombination of pElatB took place resulting in a strain containing a single amylase gene on a different locus of the 20 genome as compared with the original Bacillus licheniformis T5 amylase strain. The strain obtained containing pElatB was named TB13.

#### EXAMPLE 11

25

##### Construction of Strain T13F Containing Two Amylase Genes Separated by Endogenous Chromosomal Sequences

In order to develop a strain containing two amylase 30 genes separated by endogenous chromosomal DNA sequences, a fusion experiment was performed between Bacillus licheniformis strain T5 (the original amylase gene containing amylase strain, see EP-A-0134048) and strain TB13 (the randomly integrated, amylase gene containing strain). Protoplast fusion 35 was performed as described in EP-A-0134048, the disclosure of which is hereby incorporated by reference. Strain TB13 was killed with iodoacetamide prior to protoplast formation. Strain T5 (neomycin sensitive) was not killed. Selection for

- 22

fusants took place on the regeneration plates containing 10 ug/ml neomycin.

To check and identify potential fusants, chromosomal DNA was isolated, digested with EcoRI, fractionated on 5 0.5% agarose gels, blotted to nitrocellulose filters (Southern, J. Mol. Biol. 98 (1975) 503-517) and hybridized with <sup>32</sup>p labeled nick-translated pGB33 (see EP-A-0134048). The result of this analysis is shown in Figure 9B. One of the obtained fusants, T13F, contained two amylase genes separated 10 by endogenous chromosomal sequences.

#### EXAMPLE 12

15                    Stability of the duplicated amylase genes  
                                 in strains T390 and T13F

The stability of strain T13F, a strain containing two chromosomal amylase genes separated by essential chromosomal sequences, was compared with that of strain T390, a 20 strain with two chromosomal amylase genes located in a tandem array. Preparation of strain T390 is disclosed in EP-A-134048 (page 17, Table I), where it was referred to as B. licheniformis T5 (pGB33). Strains T13F and T390 were tested under fermentation conditions, nameley 0.2 ml of an overnight 25 TSB culture (37°C) was inoculated in 500 ml shake flasks containing 100 ml production medium (see Example 7; after sterilization the pH was adjusted to 6.9 with NaOH) without neomycin. After incubation for 6 days at 40°C under constant aeration the culture was tested for neomycin-resistant 30 colonies and amylase activity. The results of the fermentation experiments are summarized in the following Table 2.

Table 2

5	Strain	Relative Amylase Activity	Percent of Neomycin-Resistant Cells After Fermentation*
10	T5	100%	-
	TB13	20%	100%
	T13F	120%	100%
	T390	200%	88%

\* More than thousand colonies were tested per strain.

To exclude the possibility of excission of one amylase gene without concomitant loss of the neomycin gene in strain T13F, 20 colonies derived from T13F fermentation were analyzed. Chromosomal DNA from 20 randomly chosen colonies was isolated and characterized by hybridization experiments as described above. The results of 9 of these analyses are shown in Figure 10. All strains tested contained two amylase genes, as demonstrated by the presence of two alpha-amylase genes containing EcoRI fragments in their chromosomal DNA.

In contrast to the genetic stability of strain T13F, strain T390 was found to be unstable upon fermentation resulting in 12% neomycin-sensitive colonies. One of these colonies was analyzed and found to contain only one alpha-amylase gene (Figure 10, lane 4). This shows that randomly integrated amylase genes are more stable than tandemly integrated genes, under fermentation conditions.

It is evident from the above results that a prokaryotic cell may be obtained in which stable gene amplification is achieved by selecting for transformed cells in which non-tandem integration of at least two copies of the structural gene to be amplified has occurred. Integration may occur by homologous recombination or illegitimate recombination.

All publications and patent applications mentioned in this specification are indicative of the level of skill of



those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

CLAIMS

1. A transformed prokaryotic host cell comprising at least two copies of a DNA sequence in its chromosome, said  
5 DNA sequence encoding a polypeptide of interest, wherein said copies are separated by endogenous chromosomal DNA sequences.

2. A transformed prokaryotic host cell comprising at least two copies of a DNA sequence encoding a polypeptide  
10 of interest, wherein said copies are separated by endogenous chromosomal DNA sequences in the genome of said host cell, said cell being produced by the method comprising:

combining a recipient host cell comprising at least one copy of said DNA sequence integrated into its chromosome  
15 with (a) a DNA construct, comprising at least one copy of said DNA sequence and at least one of a marker gene and a temperature-sensitive origin of replication or (b) a donor host cell comprising said DNA construct, under transforming conditions;

20 selecting for a transformant wherein said DNA construct is integrated into the chromosome of said transformant; and

isolating from among said transformants, transformed prokaryotic host cells comprising at least two  
25 copies of said DNA sequence separated by endogenous DNA sequences.

3. A transformed prokaryotic host cell according to Claim 1 or 2, wherein said prokaryotic cell is a Bacillus  
30 strain.

4. A transformed prokaryotic host cell according to Claim 3, wherein said Bacillus strain is an alkalophilic Bacillus strain or a Bacillus licheniformis host strain.

35

5. A transformed prokaryotic host cell according to Claim 4, wherein said alkalophilic Bacillus strain is Bacillus novo species PB92 or a mutant or variant thereof.

6. A transformed prokaryotic host cell according to Claim 4, wherein said Bacillus licheniformis host strain is Bacillus licheniformis strain T5 or a mutant or a variant thereof.

5

7. A transformed prokaryotic host cell according to Claim 1 or 2, wherein said polypeptide of interest is an enzyme.

10 8. A transformed prokaryotic host cell according to Claim 7, wherein said enzyme is a proteolytic enzyme or an amylolytic enzyme.

9. A transformed prokaryotic host cell according to  
15 Claim 8, wherein said proteolytic enzyme is a serine protease.

10. A transformed prokaryotic host cell according to Claim 9, wherein said serine protease comprises substantially the following amino acid sequence:

20

H<sub>2</sub>N-A-Q-S-V-P-W-G-I-S-R-V-Q-A-P-A-A-H-N-R-G-L-T-G-S-G-V-K-V-A-  
V-L-D-T-G-I-S-T-H-P-D-L-N-I-R-G-G-A-S-F-V-P-G-E-P-S-T-Q-D-G-N-  
G-H-G-T-H-V-A-G-T-I-A-A-L-N-N-S-I-G-V-L-G-V-A-P-N-A-E-L-Y-A-V-  
K-V-L-G-A-S-G-S-G-S-V-S-S-I-A-Q-G-L-E-W-A-G-N-N-G-M-H-V-A-N-L-  
25 S-L-G-S-P-S-P-S-A-T-L-E-Q-A-V-N-S-A-T-S-R-G-V-L-V-V-A-A-S-G-N-  
S-G-A-G-S-I-S-Y-P-A-R-Y-A-N-A-M-A-V-G-A-T-D-Q-N-N-N-R-A-S-F-S-  
Q-Y-G-A-G-L-D-I-V-A-P-G-V-N-V-Q-S-T-Y-P-G-S-T-Y-A-S-L-N-G-T-S-  
M-A-T-P-H-V-A-G-A-A-A-L-V-K-Q-K-N-P-S-W-S-N-V-Q-I-R-N-H-L-K-N-  
T-A-T-S-L-G-S-T-N-L-Y-G-S-G-L-V-N-A-E-A-A-T-R-COOH.

30

11. A transformed prokaryotic host cell according to Claim 8, wherein said amylolytic enzyme is alpha-amylase.

12. A transformed prokaryotic host cell according to  
35 Claim 1 or 2, wherein the genome of Bacillus novo species PB92 or a mutant or variant thereof comprises said DNA sequence.

13. A transformed prokaryotic host cell according to

Claim 1 or 2, wherein the genome of Bacillus licheniformis strain T5 or a mutant or a variant thereof comprises said DNA sequence.

5           14. A method for preparing a transformed prokaryotic host cell comprising at least two copies of a DNA sequence encoding a polypeptide of interest, wherein said copies are separated by endogenous chromosomal sequences in the genome of  
10 said host cell, said method comprising:  
          combining a recipient host cell comprising at least one copy of said DNA sequence integrated into its chromosome with (a) a DNA construct, comprising at least one copy of said DNA sequence and at least one of a marker gene and a  
15 temperature-sensitive origin of replication or (b) a donor host cell comprising said DNA construct, under transforming conditions;  
          selecting for a transformant wherein said DNA construct is integrated into the chromosome of said  
20 transformant; and  
          isolating from among said transformants, transformed prokaryotic host cells comprising at least two copies of said DNA sequence separated by endogenous DNA sequences.

25           15. A method according to Claim 14, wherein said selecting comprises:  
          growing said transformant comprising a DNA construct comprising a marker gene in the presence of a  
30 biocide to which said marker gene provides resistance; and  
          identifying and isolating from said transformants, plasmid free transformants.

          16. A method according to Claim 14, wherein said  
35 selecting comprises:  
          growing said transformant comprising a DNA construct comprising a marker gene and a temperature-sensitive origin of replication in the presence of a biocide at a non-

permissive temperature; and

selecting from said transformants, plasmid free transformants.

5 17. A method according to Claim 14, wherein said isolating comprises:

isolating chromosomal DNA from said transformants;

and

hybridizing said chromosomal DNA with a labeled

10 probe comprising said DNA construct or a fragment thereof whereby said transformed prokaryotic host cells are selected by detecting said label.

18. A method according to Claim 14, wherein said 15 donor host cell is obtained by a method comprising:

combining a prokaryotic cell lacking a DNA sequence encoding said polypeptide of interest with said DNA construct under fusing conditions;

isolating transformed cells;

20 growing said transformed cells at a non-permissive temperature; and

identifying and isolating transformed cells wherein said DNA construct is integrated into a location on the chromosome other than that in said recipient host cell.

25

19. A method according to any one of Claims 14-18, wherein said prokaryotic cell is a Bacillus.

20. A method according to Claim 19, wherein said 30 Bacillus is an alkalophilic Bacillus strain or a B. licheniformis strain.

21. A method according to Claim 20, wherein said alkalophilic Bacillus strain is Bacillus novo species PB92 and 35 said B. licheniformis strain is B. licheniformis strain T5.

22. A method according to any one of Claim 14-21, wherein said polypeptide of interest is an enzyme.

23. A method according to Claim 22, wherein said enzyme is a serine protease or an amylase.

24. A method according to Claim 23, wherein said serine protease has at least 70% homology in nucleotide sequence with a proteolytic enzyme encoding gene from Bacillus novo species PB92.

25. A method according to Claim 23 or 24, wherein said serine protease has substantially the following amino acid sequence:

H<sub>2</sub>N-A-Q-S-V-P-W-G-I-S-R-V-Q-A-P-A-A-H-N-R-G-L-T-G-S-G-V-K-V-A-  
V-L-D-T-G-I-S-T-H-P-D-L-N-I-R-C-G-A-S-F-V-P-G-E-P-S-T-Q-D-G-N-  
15 G-H-G-T-H-V-A-G-T-I-A-A-L-N-N-S-I-G-V-L-G-V-A-P-N-A-E-L-Y-A-V-  
K-V-L-G-A-S-G-S-G-S-V-S-S-I-A-Q-G-L-E-W-A-G-N-N-G-M-H-V-A-N-L-  
S-L-G-S-P-S-P-S-A-T-L-E-Q-A-V-N-S-A-T-S-R-G-V-L-V-V-A-A-S-G-N-  
S-G-A-G-S-I-S-Y-P-A-R-Y-A-N-A-M-A-V-G-A-T-D-Q-N-N-N-P-A-S-F-S-  
Q-Y-G-A-G-L-D-I-V-A-P-G-V-N-V-Q-S-T-Y-P-G-S-T-Y-A-S-L-N-G-T-S-  
20 M-A-T-P-H-V-A-G-A-A-A-L-V-K-Q-K-N-P-S-W-S-N-V-Q-I-R-N-H-L-K-N-  
T-A-T-S-L-G-S-T-N-L-Y-G-S-G-L-V-N-A-E-A-A-T-R-COOH.

26. A method according to any one of Claims 14-25, wherein said DNA construct is pMAX-4 or pElatB.

25

27. A method according to any one of Claims 14-26, wherein said DNA sequence is integrated by illegitimate recombination.

30 28. A method according to any one of Claims 14-26, wherein said DNA sequence is integrated by homologous recombination.


29. A method according to any one of Claims 14-26, 35 wherein said DNA construct further comprises a temperature sensitive origin of replication.

30. A method according to of Claim 29, wherein said

temperature sensitive plasmid is derived from plasmid pE194.

31. Bacillus PBT108, PBT122, or T13F.

# A. CAMPBELL-TYPE RECOMBINATION



# B. DOUBLE RECIPROCAL RECOMBINATION





FIGURE 1



### C. TWO-STEP INTEGRATION REPLACEMENT MECHANISM



### D. INTEGRATION BY ILLEGITIMATE RECOMBINATION




FIGURE 1 (contn'd)

# A. SPREAD INTEGRATION AND AMPLIFICATION OF DNA SEQUENCES USING ILLEGITIMATE RECOMBINATION





FIGURE 2



**FIGURE 2 (contn'd)**




FIGURE 3




FIGURE 4

7/18

P1  
 20 40 60  
 GATTCTGTAACTTAACGTTAATATTTGTTTCCCAATAGGCAAATCTTTCTAACTTTGAT

P2 RBS Pre  
 80 100 120  
 ACGGTTTAACTACCAGCTTGGACAAGTTGGGATAAAAATGAGGAGGGAACCGAATGAAG

MetLys  
 1. 140 160 180  
 AAACCGTTGGGGAAAATTGTGCGCAAGCACCGCACTACTCATTCTGTTGCTTTTAGTTCA  
 LysProLeuGlyLysIleValAlaSerThrAlaLeuLeuIleSerValAlaPheSerSer

Pro 2. 240  
 200  
 TCGATCGCATCGGCTGCTGAAGAAGCAAAAGAAAAATATTTAATTGGCTTTAATGAGCAG  
 SerIleAlaSerAlaAlaGluGluAlaLysGluLysTyrLeuIleGlyPheAsnGluGln

260 280 300  
 GAAGCTGTCAGTGAGTTTGTAGAACAAGTAGAGGCAAATGACGAGGTCGCCATTCTCTCT  
 GluAlaValSerGluPheValGluGlnValGluAlaAsnAspGluValAlaIleLeuSer

320 340 3. 360  
 GAGGAAGAGGAAGTCGAAATTGAATTGCTTCATGAATTTGAAACGATTCCTGTTTTATCC  
 GluGluGluGluValGluIleGluLeuLeuHisGluPheGluThrIleProValLeuSer

380 400 420  
 GTTGAGTTAAGCCCAGAAGATGTGGACGCGCTTGAACCTCGATCCAGCGATTTCTTATATT  
 ValGluLeuSerProGluAspValAspAlaLeuGluLeuAspProAlaIleSerTyrIle

440 4. 480  
 mat  
 460  
 GAAGAGGATGCAGAAGTAACGACAATGGCGCAATCAGTGCCATGGGGAATTAGCCGTGTG  
 GluGluAspAlaGluValThrThrMetAlaGlnSerValProTrpGlyIleSerArgVal

FIGURE 5

500 520 540  
CAAGCCCCAGCTGCCCCATAACCGTGGATTGACAGGTTCTGGTGTAAGTTGCTGTCCTC  
GlnAlaProAlaAlaHisAsnArgGlyLeuThrGlySerGlyValLysValAlaValLeu

560 580 600  
5.  
GATACAGGTATTTCCACTCATCCAGACTTAAATATTCGTGGTGGCGCTAGCTTTGTACCA  
AspThrGlyIleSerThrHisProAspLeuAsnIleArgGlyGlyAlaSerPheValPro

620 640 660  
GGGGAACCATCCACTCAAGATGGGAATGGGCATGGCACGCATGTGGCTGGGACGATTGCT  
GlyGluProSerThrGlnAspGlyAsnGlyHisGlyThrHisValAlaGlyThrIleAla

680 700 720  
6.  
GCTTTAAACAATTCGATTGGCGTTCTTGGCGTAGCACCGAACGCGGAAGTATACGCTGTT  
AlaLeuAsnAsnSerIleGlyValLeuGlyValAlaProAsnAlaGluLeuTyrAlaVal

740 760 780  
AAAGTATTAGGGGCGAGCGGTTTCAGGTTTCGGTCAGCTCGATTGCCCAAGGATTGGAATGG  
LysValLeuGlyAlaSerGlySerGlySerValSerSerIleAlaGlnGlyLeuGluTrp

800 820 840  
7.  
GCAGGGAACAATGGCATGCACGTTGCTAATTTGAGTTTAGGAAGCCCTTCGCCAAGTGCC  
AlaGlyAsnAsnGlyMetHisValAlaAsnLeuSerLeuGlySerProSerProSerAla

860 880 900  
ACACTTGAGCAAGCTGTTAATAGCGGACTTCTAGAGGCGTTCTGTGTAGCGGCATCT  
ThrLeuGluGlnAlaValAsnSerAlaThrSerArgGlyValLeuValValAlaAlaSer

920 940 960  
8.  
GGGAATTCAGGTGCAGGCTCAATCAGCTATCCGGCCCGTTATGCGAACGCAATGGCAGTC  
GlyAsnSerGlyAlaGlySerIleSerTyrProAlaArgTyrAlaAsnAlaMetAlaVal

FIGURE 5 (contn'd)

9/18

	980	1000	1020
	GGAGCTACTGACCAAAACAACAACCGCGCCAGCTTTTCACAGTATGGCGCAGGGCTTGAC		
	GlyAlaThrAspGlnAsnAsnAsnArgAlaSerPh SerGlnTyrGlyAlaGlyLeuAsp		
9.	1040	1060	1080
	ATTGTCGCACCAGGTGTAAACGTGCAGAGCACATACCCAGGTTCAACGTATGCCAGCTTA		
	IleValAlaProGlyValAsnValGlnSerThrTyrProGlySerThrTyrAlaSerLeu		
	1100	1120	10. 1140
	AACGGTACATCGATGGCTACTCCTCATGTTGCAGGTGCAGCAGCCCTTGTTAAACAAAAG		
	AsnGlyThrSerMetAlaThrProHisValAlaGlyAlaAlaAlaLeuValLysGlnLys		
	1160	1180	1200
	AACCCATCTTGGTCCAATGTACAAATCCGCAATCATCTAAAGAATACGGCAACGAGCTTG		
	AsnProSerTrpSerAsnValGlnIleArgAsnHisLeuLysAsnThrAlaThrSerLeu		
	1220	1240	1260
	GGAAGCACGAACTTGTATGGAAGCGGACTTGTCAATGCAGAAGCGGCAACACGCTAATCA		
	GlySerThrAsnLeuTyrGlySerGlyLeuValAsnAlaGluAlaAlaThrArg		
	1280	1300	1320
	ATAAAACGCTGTGCTTAAAGGGCACAGCGTTTTTTTGTGTATGAATCGAAAAAGAGAAC		
	terminator		

FIGURE 5 (contn'd)






FIGURE 6A





FIGURE 6B




Lane 1: PB92

Lane 2: PBT 109

Lane 3: PBT 108

FIGURE 7A



Situation PBT109

14/18




FIGURE 7C

## CONSTRUCTION OF INTEGRATION VECTOR pELATB








FIGURE 8

16/18

-  Amylase gene
-  Neomycin resistance gene
-  Plasmid sequence
-  Chromosomal DNA




FIGURE 9A




FIGURE 9B






FIGURE 10

# INTERNATIONAL SEARCH REPORT

International Application No PCT/NL 88/00006

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>4</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>4</sup> : C 12 N 15/00; C 12 N 1/20// C 12 N 9/54																							
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">IPC<sup>4</sup></td> <td style="border: 1px solid black; padding: 5px;">C 12 N</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched <sup>8</sup></div>			Classification System	Classification Symbols	IPC <sup>4</sup>	C 12 N																	
Classification System	Classification Symbols																						
IPC <sup>4</sup>	C 12 N																						
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category <sup>9</sup></th> <th style="width: 60%;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 30%;">Relevant to Claim No. <sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">X</td> <td>EP, A, 0124374 (GENEX) 7 November 1984, see claims 1-4</td> <td style="text-align: center;">1,2,3</td> </tr> <tr> <td style="text-align: center;">Y</td> <td>see claims 10,11; page 8, lines 10-25 --</td> <td style="text-align: center;">4,6-9,11,13</td> </tr> <tr> <td style="text-align: center;">X</td> <td>EP, A, 0205371 (CNRS) 17 December 1986, see column 9, line 8; page 8, table, results QB118::(PCG1) --</td> <td style="text-align: center;">1-3,7,8,11</td> </tr> <tr> <td style="text-align: center;">X</td> <td>Chemical Abstracts, vol. 98, 1983, (Columbus, Ohio, US), J. Hofemeister et al.: "Integration of plasmid pE194 at multiple sites on the Bacillus subtilis chromosome", see page 88, abstract no. 155686a, MGG, Mol. Gen. Genet. 1983, 189(1), 58-68</td> <td style="text-align: center;">1</td> </tr> <tr> <td style="text-align: center;">A</td> <td>--</td> <td style="text-align: center;">14-16</td> </tr> <tr> <td style="text-align: center;">X</td> <td>EP, A, 0127328 (GENEX) 5 December 1984, see page 6, line 29 - page 7, line 7; page 7, lines 23-29; page 19, lines 6-11; page 19, line 34 - page 20, line 19 ./.</td> <td style="text-align: center;">1-3,7,8,11</td> </tr> </tbody> </table>			Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X	EP, A, 0124374 (GENEX) 7 November 1984, see claims 1-4	1,2,3	Y	see claims 10,11; page 8, lines 10-25 --	4,6-9,11,13	X	EP, A, 0205371 (CNRS) 17 December 1986, see column 9, line 8; page 8, table, results QB118::(PCG1) --	1-3,7,8,11	X	Chemical Abstracts, vol. 98, 1983, (Columbus, Ohio, US), J. Hofemeister et al.: "Integration of plasmid pE194 at multiple sites on the Bacillus subtilis chromosome", see page 88, abstract no. 155686a, MGG, Mol. Gen. Genet. 1983, 189(1), 58-68	1	A	--	14-16	X	EP, A, 0127328 (GENEX) 5 December 1984, see page 6, line 29 - page 7, line 7; page 7, lines 23-29; page 19, lines 6-11; page 19, line 34 - page 20, line 19 ./.	1-3,7,8,11
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>																					
X	EP, A, 0124374 (GENEX) 7 November 1984, see claims 1-4	1,2,3																					
Y	see claims 10,11; page 8, lines 10-25 --	4,6-9,11,13																					
X	EP, A, 0205371 (CNRS) 17 December 1986, see column 9, line 8; page 8, table, results QB118::(PCG1) --	1-3,7,8,11																					
X	Chemical Abstracts, vol. 98, 1983, (Columbus, Ohio, US), J. Hofemeister et al.: "Integration of plasmid pE194 at multiple sites on the Bacillus subtilis chromosome", see page 88, abstract no. 155686a, MGG, Mol. Gen. Genet. 1983, 189(1), 58-68	1																					
A	--	14-16																					
X	EP, A, 0127328 (GENEX) 5 December 1984, see page 6, line 29 - page 7, line 7; page 7, lines 23-29; page 19, lines 6-11; page 19, line 34 - page 20, line 19 ./.	1-3,7,8,11																					
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents: <sup>14</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>																							
<b>IV. CERTIFICATION</b> <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border: none;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">29th June 1988</td> <td style="border: 1px solid black; padding: 5px;">01 AUG 1988</td> </tr> <tr> <td style="border: none;">International Searching Authority</td> <td style="border: none;">Signature of Authorized Officer</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px; text-align: center;">EUROPEAN PATENT OFFICE</td> <td style="border: 1px solid black; padding: 5px;">M. VAN MOL </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	29th June 1988	01 AUG 1988	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	M. VAN MOL													
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																						
29th June 1988	01 AUG 1988																						
International Searching Authority	Signature of Authorized Officer																						
EUROPEAN PATENT OFFICE	M. VAN MOL																						

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	--	14-24, 27-30
X	EP, A, 0074553 (UNIVERSITY OF ROCHESTER) 23 March 1983, see page 16, line 34 - page 18, line 4	1-3, 7, 8, 11
Y	EP, A, 0134048 (GIST BROCADES) 13 March 1985, see the whole document	4, 6-9, 11, 13, 14-24, 27-30
X	Chemical Abstracts, vol. 108, 1988, (Columbus, Ohio, US), P. Kallio et al.: "Enhancement of alpha-amylase production by integrating and amplifying the alpha-amylase gene of Bacillus amyloliquefaciens in the genome of Bacillus subtilis", see abstract no. 88925n, Appl. Microbiol. Biotechnol. 1987, 27(1), 64-71	1, 2, 3, 7, 8, 11
A	WO, A, 86/01825 (GENEX) 27 March 1986, see page 10, line 15 - page 13, line 27; figure 2; page 16, lines 1-20	14-19, 22, 23
A	FR, A, 2292042 (GIST BROCADES) 18 June 1976	10, 24, 25
A	EP, A, 0130756 (GENENTECH) 9 January 1985, see page 4, lines 28-35; page 6, lines 21-25; page 10, lines 26-35; page 13, lines 1-8; pages 24-29; figures 1, 7	7, 8, 9, 10, 22, 23, 24, 25
A	Biological Abstracts, vol. 82, 1986, Biosciences Information Service (Philadelphia, US), J.H. Yu et al.: "Physiological properties and transformation of alkaline-tolerant bacteria", abstract no. 86427, J. Appl. Microbiol. bioeng 14(3): 239-244, 1986	4, 20
A	EP, A, 0032238 (UNIVERSITY OF ROCHESTER) 22 July 1981, see page 8, lines 1-13	
A	Gene, vol. 24, 28 September 1983, Elsevier Science Publishers (Amsterdam, NL), J.G.K. Williams et al.: "Stable integration of foreign DNA into the chromosome of the cyanobacterium Synechococcus R2", pages 37-51, see abstract; page 49, last paragraph	
E	WO, A, 87/04461 (AMGEN) 30 July 1987, see page 30, lines 3-6	1-3, 7, 8, 9

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

NL 8800006

SA 21025

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 25/07/88. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0124374	07-11-84	JP-A- 59205996	21-11-84
		US-A- 4617266	14-10-86
EP-A- 0205371	17-12-86	FR-A- 2582316	28-11-86
EP-A- 0127328	05-12-84	JP-A- 59205983	21-11-84
EP-A- 0074553	23-03-83	JP-A- 58067186	21-04-83
EP-A- 0134048	13-03-85	WO-A- 8500382	31-01-85
		AU-A- 3151084	07-02-85
		AU-B- 570709	24-03-88
WO-A- 8601825	27-03-86	EP-A- 0195078	24-09-86
		JP-T- 62500215	29-01-87
FR-A- 2292042	18-06-76	NL-A- 7513433	21-05-76
		LU-A- 73826	11-06-76
		BE-A- 835693	18-05-76
		DE-A,B,C 2551742	26-05-76
		US-A- 4002572	11-01-77
		GB-A- 1519148	26-07-78
		JP-A- 51082783	20-07-76
		JP-A- 51125407	01-11-76
		JP-A- 55148086	18-11-80
		US-E- 30602	05-05-81
		CH-A- 626916	15-12-81
		SE-A- 8104191	06-07-81
		SE-A- 7512938	19-05-76
		SE-B- 435396	24-09-84
		SE-B- 442749	27-01-86
EP-A- 0130756	09-01-85	AU-A- 2956884	03-01-85
		JP-A- 60070075	20-04-85
		EP-A- 0246678	25-11-87
		EP-A- 0247647	02-12-87
EP-A- 0032238	22-07-81	JP-A- 56113293	07-09-81
		JP-A- 62163694	20-07-87

ANNEX TO THE  
ON INTERNATIONAL PATENT APPLICATION NO.

NL 8000000  
SA 21025

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 25/07/88. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0032238		None	
WO-A- 8704461	30-07-87	AU-A- 6939887	14-08-87
		EP-A- 0254735	03-02-88

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

